A 53-year-old white woman with epidermolysis bullosa (EB) pruriginosa presented to the dermatology clinic seeking therapy for localized severe andintractable pruritus. At the age of 4 years the patient developed an extremely pruritic bullous eruption characterized by fragile blisters, erosions, andexcoriations affecting sites subject to friction and pressure, particularly the ankles and knees. By the age of 21 years, the patient had large lichenifiedplaques, areas of linear violaceous scarring, multiple milia, and erosions over much of the extensor surfaces of the legs, forearms, buttocks, and dorsumof the feet (Figure 1A and B). All of her 20 nails were grossly dystrophic (Figure 1C). Mucous membranes were normal. There was a family historyof EB pruriginosa, as the patient's younger brother and daughter were similarly affected.
Lichenified plaques, linear violaceous scarring, erosions, and milia are affecting the extensor surfaces of the legs(A), forearm (B), and feet (C). All toenails were dystrophic.
Electron microscopical features supported the diagnosis of EB pruriginosa: separation at the sublamina densa level of the dermoepidermal junction andabnormal anchoring fibrils that were scanty, disorganized, and not fully developed (Figure 2). Blood cell count andserum biochemistry findings were normal. Serum levels of thyroid hormones, ferritin, and IgE were all within normal ranges.
Electron microscopic appearances of lesional skin on the shin showing (1) keratinocytes, (2) lamina densa abovethe level of separation, (3) separation at the sublamina densa level of thedermoepidermal junction, and (4) upper dermis (original magnification ×76 000).
Throughout the course of the disease, intractable pruritus was the most prominent and severe feature, far outweighing the significant cosmetic disability.Continuous rubbing and scratching generated large areas of disease over the shins and forearms. The patient often presented with areas of frank bleedingresulting from deep excoriations. Treatments included inpatient and outpatient care with a combination of intensive emolliation, potent topical corticosteroids,sedating antihistamines, and behavioral therapy. These resulted in short-term control of the cutaneous manifestations, but not sustained improvement orcontrol of the pruritus. Thinning of the skin secondary to the ongoing use of potent topical steroids was also evident.
Epidermolysis bullosa pruriginosa is a rare condition of poorly understood pathogenesis. Therapeutic results are currently disappointing as targetedtreatments are yet to be defined. In our patient, intractable pruritus wasby far the most troublesome feature. A vicious cycle was established as theextreme itch precipitated paroxysms of scratching, resulting in new and persistent areas of disease. Our patient had been relatively unresponsive to topicalsteroids and long-term use had compounded the skin fragility by inducing significant cutaneous atrophy. The patient was reluctant to take any systemic medication.Our challenge was to find a safe and effective therapy that would target the pruritus without the side effects of topical corticosteroids.
Since systemic cyclosporine has been used in EB pruriginosa with some success,1 topical tacrolimus was consideredas an alternative therapeutic approach. Therapy was initiated with 0.03% tacrolimus ointment to the legs and forearms twice daily. Within 1 week of applying theointment, a significant decrease in the pruritus was reported, resulting in a marked reduction in scratching. Progression of the lichenified plaques,linear violaceous scars, milia, and erosions was arrested and in some areas the lichenified plaques were reduced (Figure3). The patient has used 0.03% tacrolimus ointment for 6 months without complication and remains under excellent symptomatic control.
Six months after treatment the forearms demonstrate reduction in lichenification, with persistent backgroundmilia and scarring.
Epidermolysis bullosa pruriginosa is a form of dystrophic EB characterized by prurigolike or lichenified lesions associated with scarring.2 Itis usually confined to the shins and forearms.2 The ultrastructural hallmark is a sublamina densa split associated with an alterationin the number and structure of the anchoring fibrils at the dermal-epidermal junction.2 The onset of clinical features maybe evident in early childhood, as in our patient, but in some cases appears later, in the second and third decades of life.3
The mode of inheritance is variable. McGrath et al2 described 8 unrelated cases of EB pruriginosa, of which 5 were sporadic, 2 were autosomaldominant, and 1 was recessive. Mellerio et al3 described both dominant and recessive type VII collagen gene (COL7A1) mutations underlying the EB pruriginosa phenotype. Yu-Yun Lee etal4 and Jiang et al5 examined separate Chinese families with dominant EB pruriginosa who had different COL7A1 mutations. Our patient has a brother and a daughtersimilarly affected, and the mode of inheritance appears to be autosomal dominant.
The development of EB pruriginosa phenotype has yet to be defined.6 Molecular heterogeneity and compound heterozygosity in COL7A1 mutations have been demonstrated in patientswith EB pruriginosa.3 Other genetic and environmental factors are also likely to contribute to this specific phenotype, as mutationsin COL7A1 have been demonstrated in patients with both EB pruriginosa and dystrophic EB of nonpruriginous phenotype.3
Treatment is aimed at controlling pruritus and halting the progression of cutaneous lesions. Potent topical steroids and intralesional triamcinolonehave been reported to reduce the pruritus in some cases, but do not produce sustained improvement.2 Systemic therapy withhistamine1 antihistamines, corticosteroids, or etidronate had no sustained effect.2 Oral administration of cyclosporinehas been reported in 1 case as controlling the cutaneous lesions and decreasing the pruritus.1
The aim of treatment in our patient was to eliminate the pruritus, as her scratching was traumatizing the skin and contributing to disease progression.The pathogenesis of the pruritus is poorly understood. Raised serum levels of IgE have been noted in some patients with EB pruriginosa, although elevatedIgE levels do not specifically account for a pruriginosa phenotype.3
Tacrolimus is a macrolide immunosuppressant produced by the soil fungus Streptomyces tsukubaensis. Topical application of tacrolimus in treating atopic eczema7- 10 iswell described. Cases of steroid-induced rosacea,11 pyoderma gangrenosum,12 lichen planus,13 andichthyosis linearis circumflexa14 have been successfully treated with topical tacrolimus.
Topical tacrolimus was considered in our patient because the literature suggests that it has an antipruritic action.15- 17 Theexact mode of this action is unclear. De Paulis et al16 showed that tacrolimus acted on skin mast cells challenged with anti-IgE antibodiesto inhibit histamine release in a concentration-dependent manner and impair de novo synthesis of prostaglandin D2. Eberlein-König et al17 demonstrated that tacrolimus diminished the enhancingeffect of interleukin-3 on anti-IgE-antibody–induced histamine release from basophils. The relevance of this phenomenon to EB pruriginosa is unclearbecause it is considered a mechanobullous disease.
Treatment with topical tacrolimus in our patient had minimal effect upon preexisting visible disease. The lack of a dramatic effect on establishedskin lesions was not unexpected, as EB pruriginosa is associated with an underlying COL7A1 mutation and tacrolimus does not affect collagen synthesis.18
We believe that topical tacrolimus has potential benefits over topical corticosteroids when treating EB pruriginosa. There are currently no reportsof systemic adverse effects after topical tacrolimus application.19 Although topical corticosteroids are generally well tolerated, they may cause systemic problems such as acne, hyperglycemia, growthretardation, and adrenal insufficiency when applied to large areas.20 Most importantly, tacrolimus, unlike topical steroids, does not cause cutaneous atrophy.18,21 Thesewere important considerations in our patient whose pathological cutaneous fragility was compounded by steroid-induced atrophy.
To the best of our knowledge, this is the first reported case of EB pruriginosa successfully treated with topical tacrolimus. By alleviating ourpatient's itch, disease progression was slowed and her quality of life was markedly improved. With its steroid-sparing effects and lack of documentedsystemic adverse reactions, we consider topical tacrolimus to be of significant benefit in treating EB pruriginosa.
Correspondence: Jeremy P. Banky, MBBS, Dermatology Registrar, Churchill Hospital, Oxford Radcliffe Hospitals, Headington, Oxford, OX37LJ England (email@example.com).
Accepted for publication September 23, 2003.
The authors have no relevant financial interest in this article.
Clinicians, local and regional societies, residents, and fellows are invited to submit cases of challenges in management and therapeutics to thissection. Cases should follow the established pattern. Submit 4 double-spaced copies of the manuscript with right margins nonjustified and 4 sets of theillustrations. Photomicrographs and illustrations must be clear and submitted as positive color transparencies (35-mm slides) or black-and-white prints.Do not submit color prints unless accompanied by original transparencies. Material should be accompanied by the required copyright transfer statement,as noted in "Instructions for Authors." Material for this section should be submitted to George J. Hruza, MD, Laser and Dermatologic Surgery Center Inc,14377 Woodlake Dr, Suite 111, St Louis, MO 63017.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 14
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.